JIN LEE
Nursing at Fannin St, Houston, TX

License number
Texas NP95002096
Category
Nursing
Type
Family
Address
Address 2
7501 Fannin St STE 705, Houston, TX 77054
10113 Groveland Ave, Whittier, CA 90603
Phone
(949) 218-8955

Personal information

See more information about JIN LEE at radaris.com
Name
Address
Phone
Jin Lee
478 Maria St, Santa Clara, CA 95050
Jin Lee
4817 Alexandria Ln, San Jose, CA 95129
Jin Lee, age 68
4837 Beverly Blvd APT 303, Los Angeles, CA 90004
(323) 378-5089
Jin Lee, age 95
4845 Sapphire Way, Cypress, CA 90630
(760) 868-0147
Jin Lee, age 70
4863 Castle Sword, San Antonio, TX 78218
(210) 380-7701

Professional information

See more information about JIN LEE at trustoria.com
Jin Lee Photo 1
Bioactive Egf Peptides For Promotion Of Tissue Regeneration And Cancer Therapy

Bioactive Egf Peptides For Promotion Of Tissue Regeneration And Cancer Therapy

US Patent:
5183805, Feb 2, 1993
Filed:
Aug 13, 1990
Appl. No.:
7/567407
Inventors:
Jin S. Lee - Houston TX
Mark Blick - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 3700, A61K 3702, C07K 500, C07K 700
US Classification:
514 13
Abstract:
A biologically active cyclic synthetic peptide analog having an amino acid sequence similar to that of native epidermal growth factor between amino acids 32-48 is revealed. The peptide has been found to mimic certain biological activities of intact native epidermal growth factor (EGF). The EGF peptide analogs of the present invention include at least one sulfhydryl bond between two cysteines of the peptide containing block termini. The peptides comprise the end of the B-loop and the C-loop characteristic of the native form of the epidermal growth factor peptide. The biological activity of the peptide provides for methods of using the peptide as an agent in wound healing and also in cancer therapy. More particularly, the described peptides are used in cancer therapeutic applications and in the promotion of wound healing, especially burn wounds and peptic ulcer disease. Methods of preparing and using the described bioactive EGF analog peptides are also disclosed.